ALGS · Aligos Therapeutics Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

One Corporate Drive, South San Francisco, CA, 94080, United States
Biotechnology
Healthcare

Market Cap

7.623M

52 Wk Range

$1.18 - $13.69

Previous Close

$1.25

Open

$1.26

Volume

106,836

Day Range

$1.18 - $1.34

Enterprise Value

-11.38M

Cash

31.09M

Avg Qtr Burn

N/A

Insider Ownership

10.64%

Institutional Own.

46.58%

Qtr Updated

Sep 30th 2026